دورية أكاديمية
Usefulness of methotrexate in relapsing idiopathic retroperitoneal fibrosis.
العنوان: | Usefulness of methotrexate in relapsing idiopathic retroperitoneal fibrosis. |
---|---|
المؤلفون: | Vianello F; Haematology and Clinical Immunology Unit, Department of Medicine (DIMED), University of Padova, Italy. fabrizio.vianello@unipd.it., Romano Gargarella L; Haematology Unit, Ospedale dell'Angelo, Mestre-Venezia, Italy., Cinetto F; Internal Medicine and Allergology and Clinical Immunology Units, Treviso Ca' Foncello Hospital, Treviso, Italy., Scarpa R; Internal Medicine and Allergology and Clinical Immunology Units, Treviso Ca' Foncello Hospital, Treviso, Italy., Ceccato J; Haematology and Clinical Immunology Unit, Department of Medicine (DIMED), University of Padova, Italy., Marcolongo R; Cardiology Unit, Cardioimmunology Branch, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Italy. |
المصدر: | Clinical and experimental rheumatology [Clin Exp Rheumatol] 2023 Jul; Vol. 41 (7), pp. 1544-1547. Date of Electronic Publication: 2023 Mar 09. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Clinical And Experimental Rheumatology S.A.S Country of Publication: Italy NLM ID: 8308521 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0392-856X (Print) Linking ISSN: 0392856X NLM ISO Abbreviation: Clin Exp Rheumatol Subsets: MEDLINE |
أسماء مطبوعة: | Publication: Pisa : Clinical And Experimental Rheumatology S.A.S Original Publication: Pisa, Italy : Pacini editore, [1983- |
مواضيع طبية MeSH: | Methotrexate*/adverse effects , Retroperitoneal Fibrosis*/diagnosis , Retroperitoneal Fibrosis*/drug therapy, Humans ; Recurrence ; Retrospective Studies ; Steroids/therapeutic use ; Treatment Outcome |
مستخلص: | Objectives: Glucocorticoids are the mainstay for treatment of retroperitoneal fibrosis (RPF), a disease characterised by a periaortic proliferation of fibroinflammatory tissue frequently causing urinary obstruction. The therapeutic approach to patients unsuitable for steroid therapy and to relapsing cases is still undefined. Methods: In this retrospective single-centre study we evaluated 15 patients with RPF who received second-line therapy with methotrexate (MTX) between January 2011 to December 2019. Results: Fourteen out of 15 patients (93%) showed response to MTX. Two patients experienced relapse: one patient when on MTX therapy (28 months), the other, 58 months after MTX was interrupted. Liver toxicity grade 2 was documented in 2 patients and resolved with temporary dosage reduction. One patient stopped MTX autonomously because of nausea. No severe infections were recorded. Conclusions: In selected patients with RPF who are intolerant or refractory to steroid single therapy, MTX may be considered as useful and safe second-line treatment. |
المشرفين على المادة: | YL5FZ2Y5U1 (Methotrexate) 0 (Steroids) |
تواريخ الأحداث: | Date Created: 20230313 Date Completed: 20230731 Latest Revision: 20230731 |
رمز التحديث: | 20240628 |
DOI: | 10.55563/clinexprheumatol/atxzl5 |
PMID: | 36912332 |
قاعدة البيانات: | MEDLINE |
تدمد: | 0392-856X |
---|---|
DOI: | 10.55563/clinexprheumatol/atxzl5 |